Selank and Semax are both intranasal neuropeptides developed by Russian research institutions, both demonstrating cognitive and anxiolytic profiles in preclinical models—yet their primary receptor mechanisms, downstream pathway engagement, and optimal research applications are mechanistically distinct. This comparison is intended to clarify the experimental conditions under which each peptide is the appropriate research tool, based on receptor target, circuit engagement, and validated behavioral outcome data.
Primary Mechanisms: GABA-A/Enkephalin vs ACTH/Melanocortin
Selank's primary mechanism, as reviewed separately, involves indirect GABAergic potentiation via enkephalin-degrading aminopeptidase inhibition and BDNF induction via TrkB. Its anxiolytic profile is the more extensively characterized feature: elevated plus maze, open field, and Vogel conflict test all show significant anxiolysis at 250–500 µg/kg intranasal without locomotor suppression. Semax (Met-Glu-His-Phe-Pro-Gly-Pro), a synthetic heptapeptide analog of ACTH(4-7)PGP, acts primarily via ACTH receptor-related pathways—though a specific cognate receptor has not been definitively characterized. Its established pharmacological actions include: BDNF upregulation in hippocampus and cortex (more robust than Selank—approximately 2.5–3.0-fold in hippocampus vs 1.4–1.8-fold for Selank at equivalent intranasal doses in rats); upregulation of VEGF (vascular endothelial growth factor) and NGF (nerve growth factor); and enhancement of dopaminergic and serotonergic transmission in prefrontal cortex, measured by voltammetry and microdialysis.
BDNF/TrkB: Magnitude and Regional Specificity
Both peptides induce BDNF, but differ in regional specificity and magnitude. Semax-induced BDNF upregulation is most pronounced in hippocampus and prefrontal cortex, with cortical TrkB phosphorylation documented at 1–4h post-intranasal administration. Selank's BDNF induction is hippocampally concentrated. This regional difference has implications for model selection: tasks dependent on hippocampal-prefrontal connectivity (working memory, strategy shifting) may show differential sensitivity. In Morris Water Maze studies, Semax-treated rats show ~25–30% reduction in escape latency over 5-day training versus saline controls; Selank-treated rats show statistically significant improvement in probe trial (memory consolidation) but smaller effects on acquisition speed. This pattern suggests Semax may more strongly support encoding efficiency, while Selank's anxiolytic component facilitates retrieval under stress.
Dopaminergic and Serotonergic Differences
Semax demonstrably modulates catecholaminergic transmission: acute intranasal administration in rats increases prefrontal cortex extracellular dopamine (~40% above baseline by microdialysis) and norepinephrine (~30%), with sustained elevation at 2h. Serotonergic effects include increased frontal 5-HT turnover. These monoamine effects are absent or minimal for Selank at equivalent doses—Selank studies show no significant dopamine or norepinephrine changes in PFC microdialysis. This makes Semax a more appropriate tool when catecholaminergic contributions to cognition (attention, executive function) are the research target, while Selank is more appropriate for GABAergic anxiety circuitry studies.
Comparative Research Parameters
- Selank optimal models: anxiety (EPM, Vogel conflict, stress-induced hyperthermia), GABAergic circuit assays, BDNF/TrkB hippocampal induction, enkephalin-degrading enzyme assays
- Semax optimal models: cognitive enhancement (MWM, NOR, 5-choice serial reaction time), ischemia/neuroprotection models, BDNF/VEGF induction, dopaminergic transmission (PFC microdialysis)
- Dose range (both): 100–500 µg/kg intranasal in rodents; administration in 10–20 µL volume per nostril
- Purity standard: HPLC >99%, acetate salt form, lot-traceable CoA for both; store lyophilized at −20°C with desiccant, reconstitute in sterile saline immediately before use
- Stability note: both degrade significantly in solution at room temperature; prepare fresh daily
All compounds described are for laboratory and research use only. They are not approved for therapeutic, diagnostic, or clinical use in humans. Appropriate animal research ethics protocols must be followed when conducting behavioral neuroscience studies with these compounds.